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1. Introduction 
BK virus infection is a challenging complication in renal allograft recipients and has been 
associated with hematuria, ureteral stenosis, nephropathy and malignancy. BK virus 
infection occurs early during childhood and the virus lays dormant in uroepithelial cells. 
Reactivation of the virus in renal transplant recipients is particularly worrisome because of 
its propensity to cause local damage and incite an inflammatory response leading to acute 
kidney injury and possible graft loss. Recent, OPTN (Organ Procurement and Transplant 
Network) registry analysis suggests that the incidence of BK virus related complications are 
rising and between June 2004 and December 2008, 823 grafts were lost secondary to BK 
virus related complications [1]. This review will focus on BKV nephropathy (BKVN) in renal 
allograft recipients. 
2. Early history of BKV replication 
BK virus (BKV) is a non-enveloped DNA virus that is a member of the polyomavirus family. 
It shares >70% homology to the other polyomaviruses such as JC virus, a human pathogen, 
and simian virus 40, an unclear pathogen originally identified in monkeys [2]. BKV was first 
isolated by Gardner and his colleagues in 1971 from the ureter of a renal transplant recipient 
who presented with acute renal failure and ureteral stenosis [3]. It was not until 1995, that 
the second case was identified in the kidney biopsy of a renal allograft recipient at the 
University of Pittsburgh [4]. In both cases, the patients were treated for rejection prior to 
detection of the BK virus infection. The case from Pittsburgh illustrates the complexity of 
this problem. The biopsy of the patient demonstrated virus infection and acute rejection. 
Attempts at treatment of rejection with steroids only resulted in partial response. This was 
followed by IVIG therapy and a trial of reduction in immunosuppression. Eighteen weeks 
following the initial diagnosis, the patient lost his graft. The nephrectomy specimen showed 
“moderate acute rejection, chronic vascular rejection and scattered viral inclusions.” BKV 
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replication in immunosuppressed individuals has also been reported to cause native kidney 
pathology [5-7]. 
3. Natural history of BKV replication 
By the age of 15, greater than 90% of individuals have evidence of past exposure to BKV as 
detected by BKV specific antibody response. The primary infection is associated with mild 
symptoms at best, mild upper respiratory infection or mild cystitis. The virus lies dormant 
in the uroepithelial cells in normal hosts where the intact immune system effectively 
prevents viral replication. When the host immune system is compromised, the virus, 
consisting of viral capsid proteins (VP1, VP2 & VP3) and circular double stranded DNA of 
approximately 5000 base pairs, begins its lytic life cycle [2, 8]. The virus capsid protein, VP1, 
attaches to the cell membrane via glycoproteins/gangliosides and is endocytosed via 
caveolae-mediated endocytosis. The virus is then transported to the nucleus where VP2&3 
facilitate its entry and the virus utilizes host machinery to facilitate transcription of early 
and late genes. Early gene proteins, large T antigen, truncated T antigen and small t antigen, 
facilitate DNA replication and transcription of late genes, virus capsid protein. The virus 
capsid proteins are synthesized in the cytoplasm and transported back to the nucleus for 
final virus assembly containing the dsDNA virus copy. Intranuclear assembly of multiple 
virions causes cell rupture and release of virions into the extracellular space and possible 
entry into the circulation via peritubular capillaries. 
In renal transplant recipients, BKV replication can be detected in the urine within weeks of 
transplantation. In our studies using BKV VP1 mRNA levels, we found the incidence of BKV 
replication to be 10% at 1 month, 20% at 3 months, 30% at 6 months which plateaued at 12 
month post-transplantation. Similarly other studies identified viruria rates of 19% to 49% 
within the first year post-transplantation using DNA based assays [9, 10]. Hirsch and 
colleagues detected BKV replication using decoy cells in the urine in 30% of their study 
population [11]. Following the detection of viruria, some patients develop viremia. The 
incidence of BK viremia is less common, varying from 11% to 29% [12, 13]. Viremia is 
believed to result from a more extensive infection leading to severe tubular injury with 
rupture of tubular basement membranes and entry of the virus into the blood stream via 
peritubular capillaries. Ultimately, sustained viremia is associated with BKVN in 1% to 8% 
of individuals [14]. According to recent analysis of OPTN registry data, the cumulative 
incidence of BKVN increases from 2% at one year to 3.5% at two years to 6.6% at five  
years [1].  
4. Risk factors for BKV replication and nephropathy 
Risk factors for BKV replication and nephropathy include these that affect the recipient’s 
immune response as well as other donor and recipient factors that have been linked through 
epidemiological studies. Modifiers of the immune response include immunosuppressive 
therapies, recipient humoral and cellular immunity as well as properties of the virus that 
may lead to increased virulence and immune evasion. Current data suggest that early 
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recognition of BKV replication and modulation of immune therapy, allowing for effective 
recipient response against the virus, would reduce the risk of BKV nephropathy 
significantly [15]. [Table 1] 
 
Modifiers of Effective Immune Response Other Risk Factors
1. Therapy affecting immune response 1. Donor graft factors
Induction therapy (ATG) Seropositive donor 
Tacrolimus / MMF combination maintenance 
therapy 
High donor BKV antibody titer 
High dose tacrolimus therapy Greater number of HLA 
mismatches 
Treatment of rejection post-transplantation Lack of HLA -C7 antigen 
Steroid maintenance (triple drug therapy) Ischemic injury / DGF 
2. Recipient immune memory Placement of ureteral stent 
BKV specific humoral immunity / response 2. Recipient factors
BKV specific cellular immunity / response Older age
3. Virus factors  Male gender
Virulence / Serotype(s) History of Diabetes
Immune evasion History of BKVN in previous graft 
Table 1. Risk Factors for BKV Nephropathy (BKVN) 
ATG, anti-thymocyte globulin;  HLA, human leukocyte antigen; DGF, delayed graft function ; Adopted 
from Medeiros M, Dadhania D, and Velásquez-Jones L,  "Nefropatía por virus BK" in Infecciones en el 
paciente receptor de trasplante renal (Alberú J, Morales JL; Publicaciones Permanyer; 2012) In press. 
5. Immunosuppressive agents 
The intensity of immunosuppression is the major risk factor for BKV replication and 
subsequent development of BKV nephropathy. Our center performed a prospective study to 
identify risk factors for BKV replication using BKV VP1 mRNA measurements in the urine and 
found that ATG induction (OR=5.8; P=0.008) and prednisone maintenance (OR=8.3; P=0.003) 
were independent risk factors for BKV replication in individuals maintained on tacrolimus 
and MMF [16]. In addition to potent induction therapies, treatment of acute rejection with 
steroids was also found to be an independent  risk factor for BKV replication and 
nephropathy[11][17].  
Type of maintenance immunosuppressive therapies may be an important risk factor for BKV 
nephropathy. As evidenced by low acute rejection rates, the combination of tacrolimus and 
mycophenolate mofetil is currently the most potent combination of maintenance 
immunosuppressive therapies [18-20]. Brennan and colleagues performed a prospective 
randomized controlled trial of 200 renal allograft recipients who received either tacrolimus 
or cyclosporine in combination with azathioprine (AZA) in the low risk group and MMF in 
the high risk group and found the incidence of BKV replication (viruria and viremia) to be 
highest in the tacrolimus /MMF combination (46% viruria and 13% viremia) [21]. 
 Current Concepts in Kidney Transplantation 202 
The dose of maintenance immunosuppressive therapies may also be an important factor. In 
another retrospective review of 575 renal allograft recipients, Cosio and colleagues 
evaluated the impact of tacrolimus dose on the incidence of BKV nephropathy [22]. The 
historical cohort received higher tacrolimus doses (12-15ng/ml in first month, 10-12ng/ml 
month 1 to 4, 8-10ng/ml  month 4 to 12 and then 6-8ng/ml) while the recent cohort received 
lower tacrolimus doses (10-12ng/ml in first month, 8-10ng/ml month 1-4 and 6-8ng/ml 
thereafter). The authors found a significantly lower incidence of BKV nephropathy with 
lower tacrolimus doses (3.6% in the low vs. 12.7% in the high tacrolimus group; P<0.001). In 
a recent case-controlled analysis of 99 renal allograft recipients (33 cases and 66 controls), 
the authors found higher tacrolimus levels and prednisone doses during the three months 
preceding the diagnosis of BKV nephropathy compared to the controls who had undergone 
a biopsy and did not have BKV nephropathy [23]. They performed random effects logistic 
modeling and found tacrolimus level (OR=1.3; P=0.03) and prednisone dose (OR=1.22; 
P=0.02) to be independently associated with BKVN diagnosis. MMF dose was not different 
between the two groups. 
A recent study evaluated the treatment trends for BKV replication in a cohort of 48,292 
solitary kidney transplant recipients transplanted from January 2003 to December 2006 
[1]. In their analysis, the authors found a rising trend in treatment of BKV replication, 
corresponding to an increased use of ATG (anti-thymocyte13 globulin) induction therapy 
and tacrolimus based maintenance immunosuppression. Independent risk factors for BKV 
replication include ATG induction, tacrolimus, mycophenolate mofetil (MMF) and 
prednisone maintenance therapies and treatment of acute rejection within the first six 
months after transplant. In contrast, interleukin 2 receptor (IL-2R) antibody and 
alemtuzumab induction were not associated with increased incidence of BKV associated 
treatment. mTOR inhibitor use was associated with a protective effect (HR=0.69; P=0.005) 
and may be associated with be associated with a decreased incidence of BKV 
nephropathy [1, 24]. In-vitro studies suggest that mTOR inhibitors may inhibit BKV 
replication via inhibition of large T antigen [25]. A large randomized controlled trial of 
everolimus with low dose cyclosporine versus MMF with standard cyclosporine dose 
suggested a lower incidence of BKV viruria and viremia in the everolimus treated group 
[26]. However, other studies have not demonstrated a protective effect and as a result 
larger prospective studies are needed to evaluate the role of mTOR inhibitors on BKV 
replication [18]. 
6. Recipient humoral and cellular immunity  
BKV-specific antibody response may play an important role in the risk for developing BKV 
nephropathy. Epidemiological studies suggest greater than 90% of adults have been 
exposed to BK virus during the early years [27] and have measurable humoral immunity. It 
has also been noted that the antibody titers increase with the development of BKV 
viremia/nephropathy in the post-transplant period [28]. A study of 70 renal allograft 
recipients demonstrated that pre-transplant serum anti-BKV IgG titers were lower in 
patients who went on to develop BKV viremia compared to the 17 patients who never 
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developed BKV viremia. In those that developed BKV infection, the magnitude of the rise in 
antibody titer post-transplant correlated with intensity of BKV infection [29]. The same 
authors demonstrated that the donor BKV seropositive status and the magnitude of the 
antibody titer was significantly associated with BKV replication in the recipient [30]. 
Together these data suggest that BKV-specific memory immune response is important for 
controlling BKV replication and preventing BKV nephropathy especially when the donor 
has had significant exposure to BKV as measured by BKV antibody titers.  
Recent studies have focused on measuring cellular immune response to the BK virus. 
Similar to the antibody response, BKV specific INFγ secreting T cells increase with the 
development of BKV viremia. Detection of this cellular immune response early after 
development of BKV viremia is associated with self-limited BKV infection and the 
prevention of BKV nephropathy [31, 32]. In addition, tacrolimus therapy inhibits BKV 
specific T cell immune response and reduction of immunosuppressive therapies does lead to 
an increase in the BKV specific cellular immune response [33]. Recipients who are not able 
to increase BKV specific cellular immune response promptly with BKV replication may be at 
increased risk for nephropathy and kidney damage. 
7. Other associated risk factors 
Several studies have identified the HLA type of donor and recipient to be important risk 
factors for BKV nephropathy. Although not all of the studies have found a significant 
association between HLA mismatches and risk of BKV nephropathy, Awadalla and 
colleagues found 5-6 HLA mismatches as a significant independent risk factor for BKVN 
(OR=7.6; P=0.004) in a large study cohort (n=440) with 40 BKVN patients [34]. Although no 
association was found with HLA mismatches, Bohl and colleagues found an increased risk 
of BKVN if the donor lacked HLA-Cw7 allele (RR=3.6; P=0.008) [30]. In addition, they also 
found a significantly increased risk of BKVN with positive donor serostatus for BKV IgG 
(RR=3.1. P=0.007).  
Additional recipient risk factors that have been identified are a history of diabetes, older age 
and male gender [1, 17, 35, 36]. Transplant surgery associated variables such as delayed 
graft function (DGF), ischemia, deceased donor grafts and use of ureteral stents have also 
been identified as risk factors for BKV viremia/nephropathy [1, 37, 38]. 
8. Diagnosis of BKV replication and BKVN 
8.1. Noninvasive assays for diagnosis of BKV replication 
There are several assays available for the diagnosis of BKV replication in renal allograft 
recipients. One of the earliest assays was the use of decoy cells in the urine. In this assay 
urine was examined under the microscope to look for virus infected cells that showed the 
typical ground glass appearance of the nucleus resulting from intranuclear viral inclusion 
bodies [39]. Evaluation of “negatively-stained“ urine specimens using electron microscopy 
(EM) identified the typical icosahedral shaped virions [40]. In the current era, the most 
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commonly used noninvasive assay for diagnosis of BKV replication is urine or plasma BKV 
DNA copy numbers using real-time quantitative PCR assays.  
Our center has developed and validated a noninvasive assay for the diagnosis of BKV 
replication and BKV nephropathy using urinary cell mRNA assay. In a cohort of 89 patients, 
urinary cell mRNA levels of BKV VP1 copies above 6.5x105 (copies/ng total RNA) diagnosed 
BKVN with 100% sensitivity and 97% specificity with a positive predictive value of 86% for 
BKVN [41]. More recently, urinary Haufen was introduced as an accurate predictor of 
BKVN by a group from the University of North Carolina. Urinary Haufen are “cast-like 
polyomavirus aggregates” that are detected in the urine using EM [42]. In their 
investigation, the authors compared the diagnostic utility of current noninvasive tests in 
clinical practice to urinary Haufen and found that urinary Haufen was associated with the 
highest specificity and positive predictive value. Table 2 lists the results from this study as 
well as our center‘s study of urinary cell BKV VP1 assay to provide a comprehensive view of 
all the noninvasive diagnostic assays available for BKVN.  
 
University of North Carolina – Singh et al. JASN 2009 
Test N Sensitivity Specificity PPV NPV 
Haufen  32 100% 99% 97% 100% 
Decoy Cells 32 100% 36% 40% 100% 
Urine BKV load – DNA 
>1,000 K 
32 100% 47% 44% 100% 
Plasma BKV load 
>10 K 
32 72% 88% 74% 88% 
Weill Cornell Medical Center –  Dadhania et al. Transplantation 2010 
Test N Sensitivity Specificity PPV NPV 
Urinary cell BKV VP1 
mRNA 
88 100% 97% 86% 100% 
Table 2. Non-Invasive Diagnosis of BKV Replication 
PPV: Positive Predictive Value; NPV: Negative Predictive Value 
8.2. Histological diagnosis of BKV nephropathy 
Although noninvasive assays are commonly used as a screening tool to identify BKV 
replication early, the gold standard is still the renal allograft biopsy. The diagnosis of BKVN 
is made based on the presence of typical viral cytopathic changes in the renal tubular 
epithelial cells. The presence of BKV is confirmed using an immunohistochemical (IC) 
staining of the nucleus using an antibody against the large T antigen of SV40 virus which 
cross reacts with BK and JC viruses [43]. Recently a more sophisticated assay, fluorescence 
in situ hybridization (FISH) has been developed to identify BK virus within the kidney. In a 
recent study, a side by side comparison demonstrates no clear advantage of FISH over IC 
staining [44]. BKVN progresses from early lesions demonstrating normal renal parenchyma 
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with scattered tubular epithelial cells with BK associated cytopathic changes, to significant 
tubular damage and an inflammatory response associated with tubulitis, to an advanced 
lesion where there is considerable tubular atrophy and interstitial fibrosis with chronic 
inflammation and only scattered cytopathic changes. 
A large retrospective review of BKVN associated biopsies performed by the group at the 
University of Maryland has led the way in developing the diagnostic criteria for different 
patterns of BKVN [45]. They identified three patterns of histological injury: Pattern A with 
viral cytopathic changes and almost normal parenchyma, Pattern B with viral cytopathic 
changes and significant inflammation and tubulitis with varying degrees of interstitial 
fibrosis and tubular atrophy, and Pattern C with diffuse fibrosis and tubular atrophy 
associated with some inflammation and very little viral cytopathic changes. Pattern B was 
divided into B1, B2 & B3 based on the degree of interstitial fibrosis and tubular atrophy. In 
their evaluation, they noted that Pattern A was associated with 15% risk of graft loss, Pattern 
B was associated with 25-75% risk of graft loss and Pattern C was associated with >80% risk 
of graft loss. It is important to note that in their investigation, they also found a 37% 
discordance rate between two cores of renal allograft tissue obtained from the same biopsy 
procedure within the same patient, suggesting that the pathological changes can be patchy 
in nature and a renal allograft biopsy can miss the diagnosis of BKVN.  
Recently, the Banff 2009 meeting group has collapsed these patterns into three simple stages 
– A (early), B (florid) and C (late sclerosing stage) and semiquantified the histological viral 
loads based on the cytopathic changes. At this time, there are no large studies correlating the 
use of this system with clinical outcomes [46]. However, a side by side comparison of this 
schema with an older schema demonstrated no clear advantage of the new staging system 
compared to the one developed by University of Maryland [47]. Overall, BKVN diagnosis 
associated with minimal inflammation and minimal scarring has the best prognosis and less 
than 15% risk of graft loss. The majority of patients with significant inflammation and/or 
scarring are at risk for persistent allograft dysfunction or progressive decline in renal 
function. 
The presence of the BKV associated cytopathic changes with interstitial inflammation and 
tubulitis has been the topic of discussion for some time as tubulitis is a hallmark of acute 
rejection diagnosis. Some support the notion that it represents concurrent acute rejection 
process within the allograft. However, others feel that it is difficult to separate the anti-viral 
response from the anti-allograft response. Previous studies suggested that HLA-DR staining 
of renal allograft would distinguish BKVN with rejection from BKVN alone. However, these 
data have not been validated in subsequent studies and HLA-DR staining is not used 
routinely to identify concurrent acute rejection [48, 49]. In patients with BKVN, renal tubules 
with intense cytopathic changes demonstrated positive C4d staining of the tubular basement 
membrane but not in peritubular capillaries. In a study of 113 biopsies of renal allograft 
from recipients with BKV replication, PTC (peritubular capillary) C4d staining was found to 
be a valid marker for antibody mediated rejection [50]. In patients with BKVN, renal tubules 
with intense cytopathic changes demonstrated positive C4d staining of the tubular basement 
membrane but not in peritubular capillaries.  
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The makeup of cellular infiltration in a renal allograft with BKVN is very similar to those 
with acute rejection [51]. Our group feels it is difficult to distinguish the anti-viral cellular 
response from the anti-allograft cellular response. Using the urinary cell mRNA profiles, we 
found that the granzyme B mRNA levels of BKVN patients were heterogeneous [41]. Those 
with poor graft function following BKVN had levels that were similar to those with acute 
rejection while those with stable function had granzyme B mRNA levels that were similar to 
stable patients with normal protocol biopsies. Furthermore, we found a positive relationship 
between elevated granzyme B levels and the risk for decline in graft function and a trend 
towards increased graft loss in individuals with the highest levels of urinary cell granzyme 
B mRNA.[Figure1] 
 
 
 
Figure 1. Baseline Urinary Cell Granzyme B mRNA Levels Predict Graft Function in BKVN 
Data derived from original study published by Dadhania et al. in Transplantation 2010;90(2):189-97 
9. Management of BKV replication and BKVN 
Routine monitoring of BKV replication is essential for the prevention of BKVN and 
improving renal allograft outcomes in individuals with BKVN. BKV infection progresses in 
stages, from viruria to viruria+viremia to viruria+viremia+nephropathy to graft loss. To 
prevent progression to nephropathy, intervention should begin at the stage of significant 
viruria and/or viremia. Intervention in this early stage prior to development of BKVN has 
been termed “preemptive” strategy and generally involves stepwise reduction in 
immunosuppressive therapies [15].  
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9.1. Preemptive reduction in immunosuppressive therapies 
In the current era, noninvasive monitoring for BKV replication has become a routine 
practice. Most centers have developed thresholds for initiating preemptive reduction in 
immunosuppressive therapies in the hopes of preventing BKVN. In a prospective study of 
62 renal allograft recipients, Ginevri and colleagues found the incidence of viruria to be 64% 
and viremia 22%. Of the the 13 individuals with viremia (2,460 to 170,000 copies/ml), 100% 
had clearance of viremia by median of 2 months follow up [52]. In another study of 123 
patients, 13 developed viremia in which 2 had evidence of BKVN and the remaining 11 did 
not. With reduction in immunosuppression, 10 of 11 patients without BKVN had clearance 
of viremia by median of 5 months follow up [10]. Schaub and colleagues evaluated the 
impact of a three step protocol for reduction in immunosuppression in patients with 
viremia, presumptive BKVN and biopsy confirmed BKVN. In their study, step 1 was 
reduction in tacrolimus to target trough of 6-8ng/ml, step 2 was further reduction in 
tacrolimus to 4-6ng/ml and step 3 was 50% reduction in MMF (mycophenolate mofetil). In 
their prospective study of 206 patients, they found step 1 cleared viremia in 100% of patients 
(n=8) with less than 10,000 copies/ml of BKV, 47% (8/17) of those with presumptive BKVN 
(>10,000 copies/ml of BKV) and 15% (2/13) of those with BKVN. Step 1 & 2 cleared BKV 
viremia in 88% (15/17) of those with presumptive BKVN and 61% (8/13) of those with 
BKVN. Finally, Step 1,2&3 cleared BKV viremia in 92% of individuals with biopsy proven 
BKVN. However, they found the incidence of acute rejection (subclinical + clinical) to be 
24% in those with presumptive BKVN and 38% in those with biopsy proven BKVN [49]. 
These data suggest that even with systematic monitoring for BKV viremia, a small 
percentage of patients will present with biopsy confirmed BKVN and clearance of BKV 
viremia is achieved easily in those with low copies of BKV. In those with high copies of BKV 
or presumptive BKVN, clearance of BK viremia is possible with systematic reduction in 
immunosuppressive therapies but at the expense of subclinical or clinical acute rejection 
episodes. As a result, patients who develop BKV viremia should be monitored closely, not 
only during the viremic phase but also after clearance of viremia. 
10. Management of biopsy confirmed BKVN 
The cornerstone of managing patients with BKVN is reduction in immunosuppressive 
therapies. However this strategy is associated with increased risk of acute rejection episodes 
and shorter graft survival times. Vasudev and colleagues evaluated their experience with 
BKVN by dividing their cohort into those recipients who did not have screening for BKV 
replication (n=16) and those who were diagnosed with BK viremia and subsequently found 
to have BKVN on biopsy (n=25). Renal allograft recipients were managed with reduction in 
immunosuppressive therapies and they found a three year actuarial graft survival rate of 
58%. In those who retained their grafts, the stabilization of renal function correlated with 
reduction in calcineurin inhibitors.  
The optimal management for those individuals that have BKVN with tubulitis is unclear. 
University of Pittsburgh performed a retrospe
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and tubulitis who received initial increase in immunosuppression (pulse steroids) followed 
by reduction in immunosuppression, reduction in immunosuppression only and no change 
in immunosuppression. In their study, reduction in immunosuppression compared to pulse 
steroids was associated with reduction in cytopathic changes (83% vs. 20%; P=0.004) [53]. 
Pulse steroids did result in greater improvement in tubulitis (55% vs. 26%) but this effect 
was not associated with improvement in renal function. Reduction in immunosuppression 
resulted in lower rates of graft loss in individuals with BKVN and clearance of viremia was 
associated with improved graft survival (46% vs. 25%) [47]. However, greater than 30-50% 
of individuals continue to have significant decrease in renal function [54]. 
IVIG has also been used to manage BKV replication because of its anti-inflammatory activity 
as well as the presence of humoral immunity to BKV [55, 56]. Studies indicate that treatment 
with IVIG in combination with reduction in immunosuppression is associated with 
clearance of viremia and histological clearance. Recently, a case report suggested that the 
use of IVIG was associated with increase in BKV copies [57]. Since IVIG has anti-
inflammatory properties, it is possible that use of IVIG is actually associated with an 
increase in total immunosuppression and thus results in a rise in BKV. To evaluate the use 
of IVIG as an anti-inflammatory agent that does not result in an increase in BKV replication 
requires controlled prospective trials. 
To date there are no antiviral drugs that have been proven to effectively inhibit BKV 
replication and associated graft damage. Various antivirals as well as anti-inflammatory 
agents have been used for management of BKVN in single center studies and have been 
reviewed by Rinaldo and Hirsch [58]. Cidofovir, a nucleoside analogue used for treatment 
of numerous viruses, has been used for management of BKV replication in HSCT 
(hematopoietic stem cell transplant) recipients as well in those with kidney transplants [59]. 
Treatment with cidofovir is limited by its potential for nephrotoxicity and currently, a newer 
agent that is a lipid conjugate of cidofovir, CXM001, is being studied for management of 
BKV associated hemorrhagic cystitis and BKVN [60]. Fluoroquinolones, anti-bacterial drug 
that inhibits DNA gyrase, have also been suggested to have activity against BK virus. Single 
center studies suggest that use of fluoroquinolones do result in decrease BKV replication 
[61]. However, its use in the management of BKVN has not been prospectively studied.  
In addition to anti-viral/anti-bacterial agents, agents with immunosuppressive properties 
have also been used to inhibit BKV replication. Leflunomide, an anti-inflammatory agent 
used in rheumatoid arthritis, is another agent whose metabolite inhibits protein kinase 
activity and pyrimidine synthesis. This drug has been shown to reduce BKV replication in 
some studies and the efficacy is linked to achieving drug levels above 40ug/ml. However, 
there are no randomized controlled trials demonstrating its effectiveness and it has been 
associated with significant liver toxicity. FK778 is a drug that is closely related to the active 
metabolite of leflunomide. A phase 2 randomized controlled trial that compared MMF or 
FK778 based maintenance immunosuppression did not demonstrate a benefit in preventing 
BK viruria or viremia [62]. Epidemiological studies also suggest that rapamycin, a 
maintenance immunosuppressive agent, may be associated with lower incidence of BKV 
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replication. Preliminary data suggests that initiation of rapamycin to manage BKV 
replication may be associated with faster clearance of BKV viremia [63]. Larger studies are 
necessary to clarify the role of rapamycin in the management of BKVN. 
When the patient presents with BKVN, one is obligated to intervene to avoid progression to 
graft loss. At this time, the main strategy that is employed for BKVN is reduction in 
immunosuppression. Johnston and colleagues pooled all the existing data on three different 
strategies to manage BKVN - reduction in immunosuppressive therapies (IS) alone versus 
cidofovir plus reduction in IS versus leflunomide with reduction in IS [64]. They found that 
the graft failure rate was not significantly different between the three groups. They 
concluded that there is no convincing evidence that the use of adjuvant therapies provides 
additional benefit to reduction in IS alone for management of BKVN patients.  
11. Re-transplantation in renal allograft recipients with BKVN 
Most reports indicate that risk of graft loss and persistent graft dysfunction following BKVN 
diagnosis is high [47]. Having suffered a graft loss, many of these patients return to the wait 
list with higher PRA (panel reactive antibodies) and as a result wait longer for a kidney 
transplant [65]. However, graft loss due to BKVN is not a contraindication to re-
transplantation. The most important factor in preventing BKVN in the subsequent graft is 
clearance of BKV viremia/viruria prior re-transplantation [66]. Furthermore, at this time 
there are no recommendations for avoiding any specific immunosuppressive therapy at the 
time of subsequent transplant. Most recipients with failed graft due to BKVN have been re-
transplanted with the centers’ standard immunosuppressive protocols. Of the 126 
individuals who underwent re-transplantation following graft loss attributable to BKV, BKV 
replication occurred in 17% with only 1 graft loss attributable to BKVN [65]. 
12. Summary 
BKV infection and development of BKVN in renal allograft recipients is a growing concern 
given the use of more potent immunosuppressive agents. The lack of effective anti-viral 
therapy for BKV results in a challenging management problem for transplant physicians. At 
this time, data suggest that prevention of BKVN through prospective monitoring and 
preemptive reduction in immunosuppression is a reasonable approach. Laskin and 
colleagues suggested that viruria measurement every 3 months followed by viremia 
measurement if viruria is detected is as cost-effective as viremia monitoring every 3 months. 
Patients with BKV replication or nephropathy should be monitored very closely (every two 
weeks) until viremia has cleared. Persistent viremia should lead to a kidney biopsy to assess 
the histological stage of BKV and to determine prognosis.  
The risk of graft loss remains high in individuals with BKVN and concurrent inflammation. 
There is an urgent need for randomized controlled trials to evaluate novel therapies and 
their potential advantage over reduction in immunosuppressive therapies alone. In 
addition, development and validation of noninvasive biomarkers to monitor BKV 
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replication and associated inflammatory response are necessary to enhance the management 
of allograft recipients with BKVN.  
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